Clinical application of remazolam Benzenesulfonic acid combined with propofol in endoscopic retrograde cholangiopancreatography: a randomized controlled trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300073982

Enrollment

Unknown

Registered

2023-07-26

Start date

2023-08-01

Completion date

Unknown

Last updated

2023-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Choledocholithiasis

Interventions

study group:Remazolam group received intravenous administration of Remazolam 6mg

Control group:Physiological saline placebo

Eligibility

Sex/Gender

All

Age

40 Years to 85 Years

Inclusion criteria

Inclusion criteria: ? Conduct ERCP on a scheduled basis; ? Age: 60-85 years old; ? The American Association of Anesthesiologists (ASA) is classified as Level I-III; ? Body mass index (BMI) 18-28kg/m2.

Exclusion criteria

Exclusion criteria: ? Severe hypertension or diabetes; ? Coronary heart disease; ? Central nervous system disease; ? Difficult airway; ? Allergies to the study Drug allergy; ? Intermittent or long-term use of benzodiazepines or opioids within 2 months prior to admission.

Design outcomes

Primary

Measure	Time frame
Prostaglandin 2;interleukin-17;cortisol;Dosage of propofol;	—

Secondary

Measure	Time frame
mean arterial pressure;heart rate;Oxygen Saturation;	—

Countries

China

Contacts

Public ContactLin Zeng

Shifang people's Hospital

343329636@qq.com+86 152 8147 0503

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026